Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MGCD0103 · 7 trials · 8 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | MGCD0103 administered orally three times per week. |
| Name | Type | Description |
|---|---|---|
| MGCD0103 | DRUG | MGCD0103 Administered orally three times per week. |
| Gemcitabine | DRUG | Gemcitabine 1000mg/m\<2\> intravenously days 1, 8, 15 of a 28 day cycle. |
Inclusion Criteria: * Pathologic confirmation of CLL. * Prior Treatment. There will be no limit to prior therapy. Therapy with fludarabine and Rituxan must have failed (disease progression, intolerance, or not a candidate). * Age 18 years or greater. * ECOG performance status of 0 or 1. * Laborator...
MGCD0103 is an investigational small molecule being studied for use in oncology, specifically for tumors, chronic lymphocytic leukemia, leukemia, lymphoma, and myelodysplastic syndrome. It is being developed by Bristol-Myers Squibb Company (BMY) and is currently in Phase 1 clinical development.
MGCD0103 is a small molecule being developed for oncology indications. The specific molecular target of MGCD0103 has not been disclosed in the available clinical trial information, so its mechanism of action is not detailed here.
MGCD0103 is being developed by Bristol-Myers Squibb Company, which trades under the ticker symbol BMY. The company is conducting clinical trials to evaluate this investigational drug for various oncology indications.
MGCD0103 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to evaluate its safety and efficacy in patients.
MGCD0103 has been studied in four completed Phase 1 clinical trials. These include NCT00323934 for advanced solid tumors or non-Hodgkin's lymphoma, NCT00324129 and NCT00324194 for leukemia or myelodysplastic syndromes, and NCT00372437 for tumors in combination with gemcitabine.
Yes, MGCD0103 is also referred to as MG-0103 in clinical trial documentation. The trial NCT00372437, which studies MGCD0103 in combination with gemcitabine, uses the name MG-0103 to refer to the same investigational drug.